Form 8-K - Current report:
SEC Accession No. 0000950170-25-035939
Filing Date
2025-03-10
Accepted
2025-03-10 08:31:29
Documents
12
Period of Report
2025-03-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K inzy-20250307.htm   iXBRL 8-K 51305
2 EX-99.1 inzy-ex99_1.htm EX-99.1 119264
  Complete submission text file 0000950170-25-035939.txt   301219

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inzy-20250307.xsd EX-101.SCH 25818
14 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20250307_htm.xml XML 4880
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 25722280
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)